Arcus Biosciences Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -330.4% | – | -169.9% | – | – | |
| – | +98.8% | +40.3% | -2.3% | +17.1% | -4.6% | +50.0% | +33.3% | +25.0% | +0.0% | |
| – | +450.0% | +682.6% | +131.8% | +145.0% | +150.0% | +18.2% | +12.3% | +4.1% | -21.1% | |
| – | +803.3% | +312.5% | +203.6% | +114.3% | +149.8% | +39.4% | – | – | – | |
| – | +579.1% | -94.6% | -90.6% | +166,346.4% | -280.5% | – | -111.4% | – | -981.8% | |
| – | +34.5% | -32.1% | -48.6% | +58.7% | +753.6% | -77.0% | +300.0% | -75.0% | -66.7% | |
| – | +26.3% | +131.2% | – | -833.6% | -99.1% | +10,577.4% | – | -143.3% | – | |
| – | – | – | – | – | – | – | – | – | – | |
| – | +53.7% | +16.0% | -100.1% | -42.6% | -88.9% | -100.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | +4.3% | |
| – | +53.2% | +20.2% | -99.1% | +38,962.8% | -45.9% | -86.1% | +0.0% | +739.4% | +76.2% | |
| – | +81.8% | -182.3% | – | – | -122.1% | – | -236.2% | – | +213.0% | |
| – | – | – | – | – | -361.1% | – | -176.4% | – | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.